オリゴヌクレオチド：世界市場

オリゴヌクレオチドの世界市場は、2025年に91億ドルと評価され、2025年から2030年にかけて年平均成長率（CAGR）11.5%で推移し、2030年までに157億ドルに達すると予測されています。

レポートの内容

• 64のデータ表と55の追加表
• 世界のオリゴヌクレオチド市場の詳細な分析
• 2022年から2024年までの収益（売上データ）の推移、2025年の予測、2030年までのCAGR予測を含む、世界の市場動向分析
• 世界のオリゴヌクレオチド合成市場の現在の市場規模と収益見通しの推定、および製品、用途、地域別の市場シェア分析
• 世界市場の動向、機会と抑止力、技術の進歩、規制、見通し、マクロ経済要因の影響に関する事実と数値
• ポーターのファイブフォースモデルとグローバルサプライチェーン分析から得られた洞察
• 主要な取得済みおよび公開済み特許を特集した特許レビュー
• 企業の市場シェアとランキング、製品マッピング、戦略的イニシアチブ、M&A活動、ベンチャーキャピタルの見通しを含む業界構造の分析
• 消費者の意識に重点を置いたサステナビリティのトレンドとESG動向の概要、主要企業のESGリスク評価と実践
• Alnylam Pharmaceuticals Inc.、Biogen/Ionis Pharmaceuticals Inc.、Novartis AG、Sarepta Therapeutics Inc.など、業界の主要企業の企業プロファイル

Report Highlights

The global market for oligonucleotides was valued at $9.1 billion in 2025 and is estimated to reach $15.7 billion by 2030, at a compound annual growth rate (CAGR) of 11.5% from 2025 through 2030.

Report Includes

• 64 data tables and 55 additional tables
• In-depth analysis of the global oligonucleotides market
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global oligonucleotide synthesis market, accompanied by a market share analysis by product, application and region
• Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
• Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Biogen/Ionis Pharmaceuticals Inc., Novartis AG, and Sarepta Therapeutics Inc.

Report Scope

The report provides an overview of the oligonucleotides market and analyzes market trends. It includes global revenue ($ Million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented by product type, application and region.

By product type, the market is segmented into oligonucleotide drugs, synthesized oligos, equipment and reagents, and services. The application segment is characterized by research and therapeutics and diagnostics. The report also includes an overview of the regulatory landscape for oligonucleotides.

The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, the Asia-Pacific and the rest of the world (RoW), with a focus on major countries in these regions.

The report focuses on the major driving trends and challenges affecting the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles, detailing leading market companies.

Report Synopsis

Report Includes

– 64 data tables and 55 additional tables

– In-depth analysis of the global oligonucleotides market

– Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030

– Estimates of the current market size and revenue prospects for the global oligonucleotide synthesis market, accompanied by a market share analysis by product, application and region

– Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors

– Insights derived from Porter’s Five Forces model, as well as global supply chain analyses

– Patent review, featuring key granted and published patents

– Analysis of the industry structure, including companies’ market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

– Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Biogen/Ionis Pharmaceuticals Inc., Novartis AG, and Sarepta Therapeutics Inc.

Table of Contents

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview
Types of Oligonucleotides
Mechanisms of Action of Oligonucleotides
Oligonucleotide Synthesis Processes
Solid Phase Chemical Synthesis
Porter’s Five Forces Analysis in the Global Oligonucleotides Market
Macroeconomic Factor Analysis
Impact of the U.S. Tariffs
Growing Rare Disease Funding
Geopolitical Factors
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Focus on Personalized Medicine
Increasing Use of Synthesized Oligos in Therapeutic Applications
Rising Prevalence of Rare Diseases
Market Restraints/Challenges
Product Withdrawals and Clinical Trial Failures
Complexities Associated with Oligos Manufacturing
High Treatment Costs of Oligonucleotide Therapeutics
Market Opportunities
Expanding Application Areas of Oligonucleotides
Expansion of Companies
DNA Nanotechnology for Drug Delivery
Chapter 4 Regulatory Landscape
Regulatory Paths for Oligonucleotide Therapeutics
U.S.
European Union
Asia-Pacific
Chapter 5 Emerging Technologies
Key Takeaways
Emerging Technologies
Enzymatic Oligonucleotide Synthesis
Advances in RNAi Delivery Systems
Circulating miRNA Diagnostics for Noninvasive Health Monitoring
Innovative Oligonucleotide Conjugation Methods
Pipeline Analysis
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Product Type
Key Takeaways
Oligonucleotide Drugs
Synthesized Oligos
Equipment and Reagents
Services
Market Analysis by Application
Key Takeaways
Diagnostics and Therapeutics
Research
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Industry Structure
Company Share Analysis of the Global Oligonucleotides Market
Strategic Analysis
Funding Outlook
Chapter 8 Sustainability in the Global Oligonucleotides Market: An ESG Perspective
Introduction to ESG
ESG Risk Ratings
Conclusion
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
AGILENT TECHNOLOGIES INC.
AJINOMOTO BIO-PHARMA
ALNYLAM PHARMACEUTICALS INC.
ASTELLAS PHARMA INC.
BIOGEN
CHARLES RIVER LABORATORIES
EUROFINS GENOMICS
GENSCRIPT
INTEGRATED DNA TECHNOLOGIES INC.
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
REVVITY
SAREPTA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.
Emerging Startups/Market Disruptors

List of Tables
Summary Table : Global Market for Oligonucleotides, by Region, Through 2030
Table 1 : FDA-Approved ASOs
Table 2 : RNAi-Approved Drug List
Table 3 : List of Approved Oligonucleotide Therapeutics, 2025
Table 4 : List of Selected Pipeline Oligonucleotide Molecules
Table 5 : Global Market for Oligonucleotides, by Product Type, Through 2030
Table 6 : Global Market for Oligonucleotide Drugs, by Region, Through 2030
Table 7 : Global Market for Synthesized Oligos, by Region, Through 2030
Table 8 : Global Market for Oligonucleotide Equipment and Reagents, by Region, Through 2030
Table 9 : Global Market for Oligonucleotide Services, by Region, Through 2030
Table 10 : Global Market for Oligonucleotide, by Application, Through 2030
Table 11 : Global Market for Oligonucleotides for Diagnostic and Therapeutics, by Region, Through 2030
Table 12 : Global Market for Oligonucleotides for Research, by Region, Through 2030
Table 13 : Global Market for Oligonucleotides, by Region, Through 2030
Table 14 : North American Market for Oligonucleotides, by Country, Through 2030
Table 15 : North American Market for Oligonucleotides, by Product Type, Through 2030
Table 16 : North American Market for Oligonucleotides, by Application, Through 2030
Table 17 : U.S. Market for Oligonucleotides, by Product Type, Through 2030
Table 18 : U.S. Market for Oligonucleotides, by Application, Through 2030
Table 19 : Canadian Market for Oligonucleotides, by Product Type, Through 2030
Table 20 : Canadian Market for Oligonucleotides, by Application, Through 2030
Table 21 : Mexican Market for Oligonucleotides, by Product Type, Through 2030
Table 22 : Mexican Market for Oligonucleotides, by Application, Through 2030
Table 23 : European Market for Oligonucleotides, by Country, Through 2030
Table 24 : European Market for Oligonucleotides, by Product Type, Through 2030
Table 25 : European Market for Oligonucleotides, by Application, Through 2030
Table 26 : German Market for Oligonucleotides, by Product Type, Through 2030
Table 27 : German Market for Oligonucleotides, by Application, Through 2030
Table 28 : U.K. Market for Oligonucleotides, by Product Type, Through 2030
Table 29 : U.K. Market for Oligonucleotides, by Application, Through 2030
Table 30 : French Market for Oligonucleotides, by Product Type, Through 2030
Table 31 : French Market for Oligonucleotides, by Application, Through 2030
Table 32 : Italian Market for Oligonucleotides, by Product Type, Through 2030
Table 33 : Italian Market for Oligonucleotides, by Application, Through 2030
Table 34 : Spanish Market for Oligonucleotides, by Product Type, Through 2030
Table 35 : Spanish Market for Oligonucleotides, by Application, Through 2030
Table 36 : Rest of Europe Market for Oligonucleotides, by Product Type, Through 2030
Table 37 : Rest of Europe Market for Oligonucleotides, by Application, Through 2030
Table 38 : Asia-Pacific Market for Oligonucleotides, by Country, Through 2030
Table 39 : Asia-Pacific Market for Oligonucleotides, by Product Type, Through 2030
Table 40 : Asia-Pacific Market for Oligonucleotides, by Application, Through 2030
Table 41 : Chinese Market for Oligonucleotides, by Product Type, Through 2030
Table 42 : Chinese Market for Oligonucleotides, by Application, Through 2030
Table 43 : Japanese Market for Oligonucleotides, by Product Type, Through 2030
Table 44 : Japanese Market for Oligonucleotides, by Application, Through 2030
Table 45 : South Korean Market for Oligonucleotides, by Product Type, Through 2030
Table 46 : South Korean Market for Oligonucleotides, by Application, Through 2030
Table 47 : Indian Market for Oligonucleotides, by Product Type, Through 2030
Table 48 : Indian Market for Oligonucleotides, by Application, Through 2030
Table 49 : Australian Market for Oligonucleotides, by Product Type, Through 2030
Table 50 : Australian Market for Oligonucleotides, by Application, Through 2030
Table 51 : Rest of Asia-Pacific Market for Oligonucleotides, by Product Type, Through 2030
Table 52 : Rest of Asia-Pacific Market for Oligonucleotides, by Application, Through 2030
Table 53 : RoW Market for Oligonucleotides, by Subregion, Through 2030
Table 54 : RoW Market for Oligonucleotides, by Product Type, Through 2030
Table 55 : RoW Market for Oligonucleotides, by Application, Through 2030
Table 56 : Recent Developments in the Global Oligonucleotides Market, 2022–2025
Table 57 : Key Investment Deals in the Oligonucleotides Industry, 2024 and 2025
Table 58 : Key Focus Areas in ESG Metrics
Table 59 : ESG Risk Rankings for Oligonucleotide Companies, 2025
Table 60 : Report Information Sources
Table 61 : Abbreviations Used in the Global Oligonucleotides Market
Table 62 : Agilent Technologies Inc.: Company Snapshot
Table 63 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
Table 64 : Agilent Technologies Inc.: Product Portfolio
Table 65 : Agilent Technologies Inc.: News/Key Developments, 2024
Table 66 : Ajinomoto Bio-Pharma: Company Snapshot
Table 67 : Ajinomoto Bio-Pharma: Product Portfolio
Table 68 : Ajinomoto Bio-Pharma: News/Key Developments, 2025
Table 69 : Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 70 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 71 : Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 72 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2022–2025
Table 73 : Astellas Pharma Inc.: Company Snapshot
Table 74 : Astellas Pharma Inc.: Financial Performance, FY 2023 and 2024
Table 75 : Astellas Pharma Inc.: Product Portfolio
Table 76 : Astellas Pharma Inc.: News/Key Developments, 2023
Table 77 : Biogen: Company Snapshot
Table 78 : Biogen: Financial Performance, FY 2023 and 2024
Table 79 : Biogen: Product Portfolio
Table 80 : Biogen: News/Recent Developments, 2022–2025
Table 81 : Charles River Laboratories: Company Snapshot
Table 82 : Charles River Laboratories: Financial Performance, FY 2023 and 2024
Table 83 : Charles River Laboratories: Product Portfolio
Table 84 : Charles River Laboratories: News/Key Developments, 2023
Table 85 : Eurofins Genomics: Company Snapshot
Table 86 : Eurofins Genomics: Product Portfolio
Table 87 : Eurofins Genomics: News/Key Developments, 2024
Table 88 : GenScript: Company Snapshot
Table 89 : GenScript: Financial Performance, FY 2023 and 2024
Table 90 : GenScript: Product Portfolio
Table 91 : GenScript: News/Key Developments, 2025
Table 92 : Integrated DNA Technologies Inc.: Company Snapshot
Table 93 : Integrated DNA Technologies Inc.: Product Portfolio
Table 94 : Integrated DNA Technologies Inc.: News/Key Developments, 2023
Table 95 : Merck KGaA: Company Snapshot
Table 96 : Merck KGaA: Financial Performance, FY 2023 and 2024
Table 97 : Merck KGaA: Product Portfolio
Table 98 : Merck KGaA: News/Key Developments, 2025
Table 99 : Novartis AG: Company Snapshot
Table 100 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 101 : Novartis AG: Product Portfolio
Table 102 : Novartis AG: News/Key Developments, 2023–2025
Table 103 : Novo Nordisk A/S: Company Snapshot
Table 104 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 105 : Novo Nordisk A/S: Product Portfolio
Table 106 : Novo Nordisk A/S: News/Key Developments, 2023
Table 107 : Revvity: Company Snapshot
Table 108 : Revvity: Financial Performance, FY 2023 and 2024
Table 109 : Revvity: Product Portfolio
Table 110 : Sarepta Therapeutics Inc.: Company Snapshot
Table 111 : Sarepta Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 112 : Sarepta Therapeutics Inc.: Product Portfolio
Table 113 : Sarepta Therapeutics Inc.: News/Key Developments, 2024
Table 114 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 115 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 116 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 117 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
Table 118 : List of a Few Emerging Startups

List of Figures
Summary Figure : Global Market Shares for Oligonucleotides, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis: Global Oligonucleotides Market
Figure 2 : Market Dynamics of Oligonucleotides
Figure 3 : Emerging Technologies in the Oligonucleotides Market
Figure 4 : Global Market Shares for Oligonucleotides, by Product Type, 2024
Figure 5 : Global Market Shares for Oligonucleotides, by Application, 2024
Figure 6 : Global Market Shares for Oligonucleotides, by Region, 2024
Figure 7 : North American Market Shares for Oligonucleotides, by Country, 2024
Figure 8 : European Market Shares for Oligonucleotides, by Country, 2024
Figure 9 : Asia-Pacific Market Shares for Oligonucleotides, by Country, 2024
Figure 10 : RoW Market Shares for Oligonucleotides, by Subregion, 2024
Figure 11 : Global Market Shares for Oligonucleotides, by Company, 2024
Figure 12 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 13 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 14 : Alnylam Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 15 : Astellas Pharma Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 16 : BIOGEN: Revenue Shares, by Country/Region, FY 2024
Figure 17 : Charles River Laboratories: Revenue Shares, by Business Unit, FY 2024
Figure 18 : Charles River Laboratories: Revenue Shares, by Country/Region, FY 2024
Figure 19 : GENSCRIPT: Revenue Shares, by Business Unit, FY 2024
Figure 20 : GENSCRIPT: Revenue Shares, by Country/Region, FY 2024
Figure 21 : Merck KGaA: Revenue Shares, by Business Unit, FY 2024
Figure 22 : Merck KGaA: Revenue Shares, by Country/Region, FY 2024
Figure 23 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 24 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 25 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2024
Figure 26 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2024
Figure 27 : REVVITY: Revenue Shares, by Business Unit, FY 2024
Figure 28 : REVVITY: Revenue Shares, by Country/Region, FY 2024
Figure 29 : Sarepta Therapeutics Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 30 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 31 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2024

---

---